StockData
Exelixis, Inc. logo

Exelixis, Inc. (EXEL) bonds

EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/303% above fair value
$68.50+1.40 (+2.09%)

Close on Nov 17, 2026Market cap $16.71BP/E 20.5Yield –

Debt

Borrowings on the balance sheet, Oct 2, 2026

Exelixis reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

When the debt comes due

Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2016

From the debt maturity table in the annual report (filing). “Later” is everything due after year five.

Notes and loans outstanding

As tagged in Exelixis's 10-K for the period ended Dec 31, 2021

Exelixis's filings do not break debt down by note

The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed. The repayment schedule above comes from the same report.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySize
Standby Letters of Credit$16.70M

See a number that looks wrong?